Key Takeaways From Neurocrine Biosciences Analyst Ratings
Portfolio Pulse from Benzinga Insights
Analysts have provided a range of ratings for Neurocrine Biosciences (NASDAQ:NBIX) over the past quarter, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased to $169.69, with a high estimate of $216.00 and a low estimate of $138.00. Recent analyst actions include several rating raises and price target increases.
May 28, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have shown a mix of bullish and somewhat bullish sentiments towards Neurocrine Biosciences (NASDAQ:NBIX) over the past quarter. The average 12-month price target has increased to $169.69, with several analysts raising their ratings and price targets.
The increase in the average price target and the number of analysts raising their ratings and price targets indicate positive sentiment towards NBIX. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100